EUVIMEDEUVIMED entdecken
Crossref

Anti-Gout Potential of Cleome Gynandra Aqueous Extracts: Integrated in Silico, In Vitro and in Vivo Validation

Naga Bharathi. MARNI, Madhuri. GEDELA, Indu. M, Delhi Priya BOTCHA, Hema Latha KORUPOLU, Sridevi Ranjitha. KARANAM

International Journal of Drug Delivery Technology · 04.06.2026 · 16 (46s)

DOI: 10.25258/ijddt.16.46s.52 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Drug Delivery Technology, online erschienen am 04.06.2026. Verfasst von Naga Bharathi. MARNI und 5 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Back ground: Gout pathogenesis involves hyperuricemia mediated by xanthine dehydrogenase (XDH) over activity.

Purpose

Although Cleome gynandra is traditionally utilized for inflammatory disorders, its specific anti-gout mechanisms remain scientifically uncharacterized. Material and Methods: This study investigated six major phytoconstituents for XDH (PDB: 1N5X) binding affinity using CB-Dock2, followed by in vitro enzyme inhibition assays and in vivo hyperuricemia models to establish mechanistic action and therapeutic efficacy.

Results

Phytosterols exhibited the strongest binding affinity (−10.1 kcal/mol), surpassing allopurinol (−6.1 kcal/mol). ADMET analysis (ADMET lab 2.0) confirmed drug-likeness, though phytosterols showed poor human intestinal absorption (HIA = 0.002) due to high LogP (7.9). In vitro xanthine oxidase (XO) inhibition assay revealed the aqueous extract significantly inhibited XO (IC₅₀ = 48.7 µg/mL), correlating with high glucocapparin (2.1–2.9 mg/g) and quercetin (1.7–2.1 mg/g) content (based on published HPLC data). In vivo, gout was induced in chicks (n = 3/group) using sodium bicarbonate (5g/L). Treatment with aqueous extract (100 mg/kg, p.o.) significantly reduced serum uric acid from 27.19 ± 1.83 mg/dL (gout control) to 18.87 ± 0.94 mg/dL (p < 0.01) by day 21, comparable to allopurinol (50 mg/kg).

Conclusion

Joint swelling and visceral urate deposits were markedly reduced. ALT, AST, and WBC levels normalized, confirming safety. Although phytosterols showed strong in-silico binding, their poor bioavailability limits therapeutic relevance. In contrast, glucocapparin—present in the active aqueous extract—exhibits moderate docking affinity (−7.6 kcal/mol), high HIA (0.839), and correlates with XO inhibition and uric acid reduction. These findings support C. gynandra as a promising natural candidate for gout management.

Zitieren

APA

MARNI, N. B., GEDELA, M., M, I., BOTCHA, D. P., KORUPOLU, H. L., & KARANAM, S. R. (2026). Anti-Gout Potential of Cleome Gynandra Aqueous Extracts: Integrated in Silico, In Vitro and in Vivo Validation. International Journal of Drug Delivery Technology, 16(46s). https://doi.org/10.25258/ijddt.16.46s.52

Vancouver

MARNI NB, GEDELA M, M I, BOTCHA DP, KORUPOLU HL, KARANAM SR. Anti-Gout Potential of Cleome Gynandra Aqueous Extracts: Integrated in Silico, In Vitro and in Vivo Validation. International Journal of Drug Delivery Technology. 2026;16(46s). doi:10.25258/ijddt.16.46s.52

BibTeX
@article{MARNI2026,
  author = {MARNI, Naga Bharathi. and GEDELA, Madhuri. and M, Indu. and BOTCHA, Delhi Priya and KORUPOLU, Hema Latha and KARANAM, Sridevi Ranjitha.},
  title = {Anti-Gout Potential of Cleome Gynandra Aqueous Extracts: Integrated in Silico, In Vitro and in Vivo Validation},
  journal = {International Journal of Drug Delivery Technology},
  year = {2026},
  volume = {16},
  number = {46s},
  doi = {10.25258/ijddt.16.46s.52}
}
Kostenlos starten →